Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug

Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.

Inside Waisman: Meet Lindsay McCary

As a third year graduate student in school psychology at the University of South Carolina, Lindsay McCary, PhD, was looking for a new advisor to help her with her dissertation. At the time, Jane Roberts, PhD, had just joined the Department of Psychology and had some data available on younger children with the genetic disorder fragile X syndrome (FXS). McCary was immediately fascinated by the new professor’s research because it integrated both behavioral and physiological data to examine an individual’s observable characteristics.

The ECHO Effect

Project ECHO (the mantra for which is “All teach, all learn”) uses video-conferencing technology to provide education and case consultation on best practice clinical services, training, and resources for individuals with specific healthcare needs that are difficult to meet locally. The Waisman Center ECHO platform will serve as a diagnostic and treatment training hub to share the center’s expertise on intellectual and developmental disabilities, such as autism, Down syndrome, and cerebral palsy, throughout the state and beyond.